Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Enzymatica AB (publ)    ENZY   SE0003943620

ENZYMATICA AB (PUBL)

(ENZY)
  Report
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Enzymatica publ : and STADA extend agreement for Europe

share with twitter share with LinkedIn share with facebook
05/25/2020 | 04:00am EDT

Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect® (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The launch of ViruProtect in these new markets is expected to the fall of 2020.

Enzymatica and STADA have an agreement for sales and distribution of ViruProtect in Belgium and Austria since 2017. This agreement is now extended to another 19 countries in Europe. Most of these markets are countries in Eastern Europe but do also include a few Western European markets. The OTC Cough/Cold/Flu/Sore Throat market in these countries totals SEK 23.6 billion[1)] (ex factory sales). The estimated annual growth rate over the next five years

is 2.4%. [1)]

ViruProtect will be sold as a medical device in the countries covered by the extended agreement, and the first deliveries are expected to take place after the summer. The ordered volumes include both 7 ml and 20 ml bottles of ViruProtect.

"We are very pleased that STADA has great trust in our cold spray and has now extended our agreement to a large amount of markets in Europe. With a proven success of ColdZyme in a number of existing markets, there is a strong potential for further growth of our business in Europe," says Fredrik Lindberg, CEO of Enzymatica.

1. [Nicholas Hall, 2018]

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 10 am CET on May 25, 2020.

For more information, please contact:

Claus Egstrand, Chief Operating Officer Enzymatica AB
Phone: +44 7780 22 8385 | E-mail: claus.egstrand@enzymatica.com

Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: carl-johan.wachtmeister@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily

conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica's certified adviser is Erik Penser Bank.  Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se

Enzymatica AB Ideon Science Park, SE-223 70 Lund, Sweden Telefon +46 46-286 31 00

https://news.cision.com/enzymatica-ab/r/enzymatica-and-stada-extend-agreement-for-europe,c3118882

https://mb.cision.com/Main/18091/3118882/1252908.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
Latest news on ENZYMATICA AB (PUBL)
06/03ENZYMATICA PUBL : Shorter duration of common colds for endurance athletes with C..
AQ
05/25ENZYMATICA PUBL : and STADA extend agreement for Europe
AQ
05/19ENZYMATICA PUBL : Grant of European patent for ColdZyme
AQ
05/18ENZYMATICA PUBL : Changes in management at Enzymatica
AQ
05/05ENZYMATICA PUBL : Bulletin from Annual General Meeting in Enzymatica AB (publ)
AQ
05/05ENZYMATICA PUBL : Doubled sales and positive earnings for the first quarter
AQ
04/24ENZYMATICA PUBL : ColdZyme re-certified to class III in the EU
AQ
04/21ENZYMATICA PUBL : enables postal voting at the Annual General Meeting 2020
AQ
04/03ENZYMATICA PUBL : Notice of annual general meeting 2020 in Enzymatica AB (publ)
AQ
04/02ENZYMATICA PUBL : - publication of the Annual Report 2019
AQ
More news
Financials (USD)
Sales 2020 12,2 M - -
Net income 2020 -0,41 M - -
Net cash 2020 1,63 M - -
P/E ratio 2020 -607x
Yield 2020 -
Capitalization 260 M 260 M -
EV / Sales 2019
EV / Sales 2020 21,2x
Nbr of Employees 17
Free-Float 99,0%
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price
Last Close Price 16,80 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Ann Therese Camilla Filmersson Chief Executive & Financial Officer
Bengt Baron Chairman
Claus Egstrand Chief Operating Officer
Johan Lindvall Chief Technology Officer
Fredrik Lindberg Director
Sector and Competitors
1st jan.Capitalization (M$)
ENZYMATICA AB (PUBL)260
BY-HEALTH CO., LTD.32.35%4 820
BALCHEM CORPORATION-9.86%2 964
THE SIMPLY GOOD FOODS COMPANY-25.33%2 115
MEDIFAST, INC.36.40%1 761
KOLMARBNH CO LTD--.--%1 298